Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address crawf006@mc.duke.edu

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974

Publications

Dale, David C., Jeffrey Crawford, Zandra Klippel, Maureen Reiner, Timothy Osslund, Ellen Fan, Phuong Khanh Morrow, Kim Allcott, and Gary H. Lyman. “A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.” Support Care Cancer 26, no. 1 (January 2018): 7–20. https://doi.org/10.1007/s00520-017-3854-x.

PMID
28939926
Full Text

Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.

PMID
28951518
Full Text

Crawford, Jeffrey, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, et al. “Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 12 (December 2017): 1520–41. https://doi.org/10.6004/jnccn.2017.0175.

PMID
29223990
Full Text

Le-Rademacher, Jennifer G., Jeffrey Crawford, William J. Evans, and Aminah Jatoi. “Overcoming obstacles in the design of cancer anorexia/weight loss trials.” Critical Reviews in Oncology/Hematology 117 (September 2017): 30–37. https://doi.org/10.1016/j.critrevonc.2017.06.008.

PMID
28807233
Full Text

Tandberg, Daniel J., Chris R. Kelsey, Thomas A. D’Amico, Jeffrey Crawford, Junzo P. Chino, Betty C. Tong, Neal E. Ready, and Ato Wright. “Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall.” Clin Lung Cancer 18, no. 4 (July 2017): e259–65. https://doi.org/10.1016/j.cllc.2016.11.008.

PMID
27965012
Full Text

Winckworth-Prejsnar, Katy, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C Lyn Fitzgerald, and Robert W. Carlson. “Developments in Molecular Testing and Biosimilars.” J Natl Compr Canc Netw 15, no. 6 (June 2017): 772–82. https://doi.org/10.6004/jnccn.2017.0109.

PMID
28596257
Full Text

Wade, James Lloyd, Corey J. Langer, Mary Redman, Charu Aggarwal, Jeffrey D. Bradley, Jeffrey Crawford, Jieling Miao, et al. “A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.” In Journal of Clinical Oncology, 35:9054–9054. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.9054.

Full Text

Baggstrom, Maria Q., Mark A. Socinski, Xiaofei F. Wang, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker, et al. “Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).” J Thorac Oncol 12, no. 5 (May 2017): 843–49. https://doi.org/10.1016/j.jtho.2017.01.022.

PMID
28161554
Full Text

Yi, John, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, Mark W. Onaitis, Chelsae Dumbauld, et al. “Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, 35:26–26. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.7_suppl.26.

Full Text

Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors.” Cancer Chemother Pharmacol 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.

PMID
28238078
Full Text

Pages